SonoThera develops nonviral genetic medicine utilizing an ultrasound-mediated delivery platform. This technology is designed to address prevailing limitations in gene therapy concerning safety, efficacy, and biodistribution. The company aims to provide next-generation genetic medicines to treat the root causes of various human diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Systemic chemotherapy often results in suboptimal drug concentrations at the tumor site while exposing healthy tissue to toxic side effects. Conventional delivery methods lack spatial precision, leading to dose‑limiting toxicities and reduced therapeutic windows. In many oncology indications, the inability to control drug release in real time hampers efficacy and patient compliance.
Solution
Sonothera Bio offers a focused‑ultrasound‑mediated drug delivery platform that activates therapeutic agents only within the targeted disease locus. The system combines image‑guided high‑intensity focused ultrasound (HIFU) with engineered carrier formulations—such as microbubble‑encapsulated small molecules or biologics—that remain inert in circulation. Upon exposure to a calibrated acoustic pressure field, the carriers undergo rapid cavitation or thermal disruption, releasing the payload locally and instantaneously. This non‑invasive approach decouples systemic exposure from therapeutic effect, enabling higher local drug concentrations without increasing overall dose. The platform is compatible with existing clinical imaging suites (MRI, ultrasound) and can be integrated into standard oncology treatment workflows. By providing programmable, spatially confined release, Sonothera aims to expand the therapeutic index of both established chemotherapies and emerging targeted agents.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology therapeutics that require enhanced delivery precision, as well as academic and hospital oncology centers seeking to implement non‑invasive, image‑guided drug activation in clinical trials.
Features
- High‑intensity focused ultrasound transducer array with real‑time beam steering for sub‑centimeter targeting accuracy
- Proprietary carrier particles (e.g., lipid‑based microbubbles, polymeric nanocapsules) engineered for ultrasound‑triggered payload release
- Integrated imaging feedback loop (MRI‑compatible or ultrasound‑based) that monitors cavitation events and verifies release kinetics in situ
- Modular formulation pipeline supporting small‑molecule drugs, peptides, and antibody‑drug conjugates across multiple disease indications
- Closed‑loop control software that adjusts acoustic parameters based on tissue acoustic impedance and temperature measurements
- GMP‑compliant manufacturing process for scalable production of ultrasound‑responsive carriers
- Compatibility with existing clinical workflows through standard DICOM interfaces and optional bedside console deployment